Chapter 029

Pituitary, Thyroid, and Parathyroid Pharmacology

Gail T. Galasko

GENERAL REFERENCES

  1. Drugs for post-menopausal osteoporosis, Med Lett Drugs Ther 56(1452):91–96, 2014. PUBMED Abstract
  2. Heaney RP, Vitamin D: Role in the Calcium and Phosphorus Economies. In 3rd ed., Feldman D, Pike JW, Adams JS, editors: Vitamin D, vol 1. New York, 2011, Academic Press. (Chapter 34).
  3. Jarnbring F, Kashani A, Bjork A, Hoffman T, et al.: Role of intravenous dosage regimens of bisphosphonates in relation to other etiological factors in the development of osteonecrosis of the jaws in patients with myeloma, Br J Oral Maxillofacial Surg, 2015. In press, available online Nov. 1, 2015. PUBMED Abstract
  4. Little JW: Medical management update: Thyroid disorders, Part I: Hyperthyroidism, Oral Surg, Oral Med, Oral Path, Oral Radiol Endocrinol 101:276–284, 2006.
  5. Pazianas M: Anabolic effects of PTH and the “anabolic window”, Trends Endocrinol Metab 26:111–113, 2015. PUBMED Abstract
  6. Recombinant human parathyroid hormone (Natpara), Med Lett Drugs Ther 57(1470):87–88, 2015. PUBMED Abstract
  7. Sisson JC, Freitas J, McDougall IR, Dauer LT, et al.: Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: Practice recommendations of the American Thyroid Association. From the American Thyroid Association Taskforce on Radioiodine Safety, Thyroid 21:335–346, 2011. PUBMED Abstract